NCT07080346View on ClinicalTrials.gov

Upadacitinib for Refractory Behcet's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

July 8, 2025

Conditions
Behcet Syndrome
Interventions
DRUG

Upadacitinib 15 MG

All the BS patients discontinued other biologic agents and received oral upadacitinib treatment at a dose of 15mg per day with background glucocorticoids and immunosuppressants for 48 weeks. All the patients will be followed up prospectively for 48 weeks.

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Liu Tian

OTHER

NCT07080346 - Upadacitinib for Refractory Behcet's Syndrome | Biotech Hunter | Biotech Hunter